博瑞医药跌2.06%，成交额2.34亿元，主力资金净流出1119.33万元

Core Viewpoint - 博瑞医药's stock has experienced significant fluctuations, with a year-to-date increase of 73.60% but a recent decline of 5.55% over the past five trading days, indicating volatility in investor sentiment and market performance [1]. Financial Performance - For the period from January to September 2025, 博瑞医药 reported a revenue of 874 million yuan, representing a year-on-year decrease of 10.50%. The net profit attributable to shareholders was 50.32 million yuan, down 71.64% compared to the previous year [2]. - Cumulative cash dividends since the A-share listing amount to 246 million yuan, with 129 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of September 30, 2025, 博瑞医药 had 19,600 shareholders, an increase of 104.44% from the previous period. The average number of circulating shares per shareholder decreased by 51.05% to 21,629 shares [2]. - The stock's trading activity showed a net outflow of 11.19 million yuan from major funds, with significant selling pressure observed [1]. Company Overview - 博瑞医药, established on October 26, 2001, and listed on November 8, 2019, focuses on the research and production of high-end generic drugs and original new drugs. The main revenue sources are product sales (89.90%), technical rights and services (6.77%), and other income (3.33%) [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and raw materials [1].